GSA Capital Partners LLP Cuts Holdings in Ocugen, Inc. $OCGN

GSA Capital Partners LLP trimmed its position in Ocugen, Inc. (NASDAQ:OCGN) by 39.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,041,598 shares of the company’s stock after selling 686,963 shares during the quarter. GSA Capital Partners LLP’s holdings in Ocugen were worth $1,698,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in Ocugen during the 2nd quarter valued at approximately $333,000. Vanguard Personalized Indexing Management LLC boosted its position in shares of Ocugen by 48.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company’s stock valued at $29,000 after acquiring an additional 9,791 shares during the last quarter. Ethic Inc. bought a new position in shares of Ocugen during the 2nd quarter valued at approximately $40,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Ocugen in the second quarter valued at $130,000. Finally, Verdence Capital Advisors LLC bought a new stake in Ocugen in the third quarter worth $47,000. 10.27% of the stock is owned by institutional investors.

Ocugen Stock Performance

Shares of NASDAQ:OCGN opened at $1.44 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 8.04. Ocugen, Inc. has a 12 month low of $0.52 and a 12 month high of $1.96. The company has a market capitalization of $449.74 million, a price-to-earnings ratio of -6.55 and a beta of 3.49. The firm’s 50-day moving average is $1.49 and its 200 day moving average is $1.36.

Wall Street Analysts Forecast Growth

OCGN has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Ocugen in a research report on Tuesday, January 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.00.

Ocugen Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.